http://rdf.ncbi.nlm.nih.gov/pubchem/reference/5874515

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 131
issn 0167-6806
1573-7217
issueIdentifier 1
pageRange 121-131
publicationName Breast Cancer Research and Treatment
startingPage 121
bibliographicCitation Barrios CH, Liu M, Lee SC, Vanlemmens L, Ferrero J, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Research and Treatment. 2010 Mar 26;121(1):121–31. doi: 10.1007/s10549-010-0788-0.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c8de6f53b3dd8d8fcfc30d39209236e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e717c369c2a4ea2b1c7d4aa11c35a4dd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e3dd0bd284d5b2b2b9341505b8170e72
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f58e4c071ff50ce625628f46c68037ba
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f73130b0fac7bfb98070f45d0f11afd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_17c94402200378a47d656da5ec09840d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f36002edab12335f67d4c08e5eb68253
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e7e96d1e5af6a213c80c38b0f7478e71
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e10796682f399d122ce76eb5971c8e30
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27391774d9cf76877f458bce79fbfa66
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_de0febf863dba93b6bf2a39a46059201
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c08842891e752091b5968328aa0a780
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_199b1c76da2d06355d017d6cbbff2790
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6ee920573689aeec1de730f9c735ea9f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d1f9fc0e13597d8ffc4c58a4389720fe
date 2010-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/PMC2855860
https://pubmed.ncbi.nlm.nih.gov/20339913
https://doi.org/10.1007/s10549-010-0788-0
isPartOf https://portal.issn.org/resource/ISSN/1573-7217
https://portal.issn.org/resource/ISSN/0167-6806
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1254
language English
source https://www.crossref.org/
https://scigraph.springernature.com/
https://pubmed.ncbi.nlm.nih.gov/
title Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
discusses http://id.nlm.nih.gov/mesh/M0448793
http://id.nlm.nih.gov/mesh/M0018276
http://id.nlm.nih.gov/mesh/M0008631
http://id.nlm.nih.gov/mesh/M0287377
http://id.nlm.nih.gov/mesh/M0011238
http://id.nlm.nih.gov/mesh/M0001483
http://id.nlm.nih.gov/mesh/M0005997
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5329102
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9548828
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127494626
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247499656
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128433595
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129555111
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128611606
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135808554
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127925204
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129138006

Total number of triples: 62.